Insider Transactions in Q3 2025 at Ani Pharmaceuticals Inc (ANIP)
Insider Transaction List (Q3 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 19
2025
|
Krista Davis SVP, CHIEF HR OFFICER |
SELL
Open market or private sale
|
Direct |
1,000
-1.63%
|
$98,000
$98.04 P/Share
|
|
Sep 12
2025
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
400
-0.52%
|
$39,200
$98.42 P/Share
|
|
Sep 12
2025
|
Krista Davis SVP, CHIEF HR OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,710
-2.72%
|
$165,870
$97.71 P/Share
|
|
Sep 03
2025
|
Antonio R Pera Director |
SELL
Open market or private sale
|
Direct |
7,292
-24.35%
|
$685,448
$94.94 P/Share
|
|
Aug 25
2025
|
Matthew J Leonard Director |
SELL
Open market or private sale
|
Direct |
2,528
-26.92%
|
$227,520
$90.62 P/Share
|
|
Aug 22
2025
|
Krista Davis SVP, CHIEF HR OFFICER |
SELL
Open market or private sale
|
Direct |
1,763
-2.73%
|
$160,433
$91.1 P/Share
|
|
Aug 21
2025
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
52,988
-10.93%
|
$4,768,920
$90.44 P/Share
|
|
Aug 20
2025
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
47,012
-8.84%
|
$4,231,080
$90.27 P/Share
|
|
Aug 20
2025
|
Antonio R Pera Director |
SELL
Open market or private sale
|
Direct |
5,421
-15.33%
|
$482,469
$89.73 P/Share
|
|
Aug 18
2025
|
Jeanne Thoma Director |
SELL
Open market or private sale
|
Direct |
21,540
-26.91%
|
$1,917,060
$89.32 P/Share
|
|
Aug 18
2025
|
Matthew J Leonard Director |
SELL
Open market or private sale
|
Direct |
6,937
-42.48%
|
$610,456
$88.17 P/Share
|
|
Aug 15
2025
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
52,990
-9.06%
|
$4,610,130
$87.15 P/Share
|
|
Aug 15
2025
|
Patrick D Walsh Director |
SELL
Open market or private sale
|
Direct |
9,000
-11.39%
|
$801,000
$89.05 P/Share
|
|
Aug 15
2025
|
Chad Gassert SVP - CORP. DEV. & STRATEGY |
SELL
Open market or private sale
|
Indirect |
20,000
-10.35%
|
$1,720,000
$86.97 P/Share
|
|
Aug 14
2025
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
47,010
-7.44%
|
$4,183,890
$89.48 P/Share
|
|
Aug 13
2025
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
400
-0.52%
|
$35,200
$88.87 P/Share
|
|
Aug 12
2025
|
Thomas Andrew Rowland SVP, HEAD - ESTABLISHED BRANDS |
SELL
Open market or private sale
|
Direct |
4,975
-10.87%
|
$422,875
$85.71 P/Share
|
|
Aug 12
2025
|
Ori Gutwerg SVP, GENERICS |
SELL
Open market or private sale
|
Direct |
5,873
-6.53%
|
$505,078
$86.53 P/Share
|
|
Aug 12
2025
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Open market or private sale
|
Direct |
56,960
-12.17%
|
$4,841,600
$85.93 P/Share
|
|
Aug 12
2025
|
Stephen P. Carey SVP & CFO |
SELL
Open market or private sale
|
Direct |
50,000
-21.66%
|
$4,300,000
$86.07 P/Share
|
|
Aug 12
2025
|
Stephen P. Carey SVP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+17.8%
|
$2,300,000
$46.49 P/Share
|
|
Aug 12
2025
|
Thomas Haughey Director |
SELL
Open market or private sale
|
Direct |
19,341
-34.62%
|
$1,643,985
$85.93 P/Share
|
|
Jul 18
2025
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Payment of exercise price or tax liability
|
Direct |
2,071
-2.62%
|
$136,686
$66.3 P/Share
|
|
Jul 14
2025
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
400
-0.5%
|
$25,600
$64.88 P/Share
|